View full metadata

THIS DOI METADATA WAS LAST UPDATED: 2024-01-10 22:57

DOI data

10.3280/RSF2016-002002

Serial Article

Cite as

Journal Data
Journal Issue Data
Serial Article Data
Reference list of 10.3280/RSF2016-002002

Unstructured Citation

[1] Barbato A. È al tramonto l’età d’oro degli psicofarmaci: verso un uso critico al di là del trionfalismo. Rivista Sperimentale di Freniatria 2015; CXXXIX: 100-12.

https://doi.org/10.3280/RSF2015-001008

Unstructured Citation

[2] Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale Gennaio-Settembre 2014. Roma: Agenzia Italiana del Farmaco; 2015.

Unstructured Citation

[3] Parabiaghi A, Franchi C, Tettamanti M, Barbato A, D’Avanzo B, Fortino I, et al. Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. European Journal of Clinical of Pharmacology 2011; 67:1077-83.

https://doi.org/10.1007/s00228-011-1054-z

Unstructured Citation

[4] Moncrieff J Antipsychotic Maintenance Treatment: Time to Rethink? Plos Medicine 2015; 12: e1001861.

https://doi.org/10.1371/journal.pmed.1001861

Unstructured Citation

[5] Moncrieff J, Cohen D, Porter S. The psychoactive effects of psychiatric medication: the elephant in the room. Journal of Psychoactive Drugs 2013; 45:409-15.

https://doi.org/10.1080/02791072.2013.845328

Unstructured Citation

[6] Kirsch I. Antidepressants and placebo effect. Zeitschrift für Psychologie 2014; 222: 128-134.

https://doi.org/10.1027/2151-2604/a000176

Unstructured Citation

[7] Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008; 358: 252-260.

https://doi.org/10.1056/NEJMsa065779

Unstructured Citation

[8] Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341.

https://doi.org/10.1016/S0140-6736(04)16043-1

Unstructured Citation

[9] Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53.

https://doi.org/10.1001/jama.2009.1943

Unstructured Citation

[10] Doshi P, Dickersin K, Healey D, Vedula SS. Restoring invisible and abandoned trials: a call for people to publish the findings. British Medical Journal 2013; 346: f2865.

https://doi.org/10.1136/bmj.f2865

Unstructured Citation

[11] Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013, 70:913-920. [12] Alvarez-Jimenez M, O’Donoghue B, Thompson A, Gleeson JF, Bendall S, Gonzalez-Blanch C, et al. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. CNS drugs 2016; 1-12.

Unstructured Citation

[13] Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 2002; 106: 286-90.

https://doi.org/10.1034/j.1600-0447.2002.02437.x

Unstructured Citation

[15] Álvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry 2008; 193: 101–7.

https://doi.org/10.1192/bjp.bp.107.042853

Unstructured Citation

[16] Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 2007; 64: 1123-31.

https://doi.org/10.1001/archpsyc.64.10.1123

Unstructured Citation

[17] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.

https://doi.org/10.1001/jama.288.21.2709

Unstructured Citation

[18] Curtis J, Henry C, Watkins A, Newall H, Samaras K, Ward PB. Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic crosssectional study. Early Intervention in Psychiatry 2011; 5: 108-14.

https://doi.org/10.1111/j.1751-7893.2011.00262.x

Unstructured Citation

[19] Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin 2010; 36: 94-103.

https://doi.org/10.1093/schbul/sbp130

Unstructured Citation

[20] Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353: 1209-23.

https://doi.org/10.1056/NEJMoa051688

Unstructured Citation

[21] Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: CostUtility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006; 63: 1079–1087.

https://doi.org/10.1001/archpsyc.63.10.1079

Unstructured Citation

[22] Parabiaghi A, Tettamanti M, D’Avanzo B, Barbato A, GISAS Study Group. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatrica Scandinavica 2016; 133: 63-75.

https://doi.org/10.1111/acps.12468

Unstructured Citation

[23] Cheng F, Jones PB. Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design. Epidemiology and Psychiatric Sciences 2013; 22: 223-33.

https://doi.org/10.1017/S204579601200073X

Unstructured Citation

[24] Ghio L, Natta W, Barbato A, Marcenaro M, Gotelli S, Jones PB, Parabiaghi A. Schizophrenia trial participation: perceived inclusion barriers and beliefs about antipsychotics. Pharmacopsychiatry 2011; 44: 123-128.

https://doi.org/10.1055/s-0031-1277147

Unstructured Citation

[25] Coleman R. Guarire dal male mentale. Roma: Manifestolibri; 2001.

Unstructured Citation

[26] Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatric Services 2006; 57:1636-9.

https://doi.org/10.1176/ps.2006.57.11.1636

Unstructured Citation

[27] Barbato A, Vallarino M, Rapisarda F, Lora A, Parabiaghi A, D’Avanzo B, et al. Do people with bipolar disorders have access to psychosocial treatments? A survey in Italy. International Journal of Social Psychiatry 2016; E-pub

Unstructured Citation

[28] Masciarri D, Natali D, Palazzari F. I farmaci da dentro. Presentato al Congresso Europeo della World Association for Psychosocial Rehabilitation 2015; Torino.

Unstructured Citation

[29] Progetto Contraria-Mente. Sospendere gli psicofarmaci. Manuale per la riduzione del danno. New York e Northampton: Icarus Project e Freedom Center; 2010.

Unstructured Citation

[30] Barbato A. La terapia farmacologica a lungo termine favorisce la guarigione dalle psicosi? In: Maone A, D’Avanzo B, ed. Recovery. Nuovi paradigmi per la salute mentale. Milano: Raffaello Cortina; 2015.

Unstructured Citation

[31] Bramesfeld A, Wedegärtner F, Elgeti H, Bisson S. How does mental health care perform in respect to service users’ expectations? Evaluating in patient and outpatient care in Germany with the WHO responsiveness concept. BMC Health Services Research 2007; 7:99-110.

https://doi.org/10.1186/1472-6963-7-99